PDF] Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy? | Semantic Scholar
CA 19-9 – Pancreatic Cancer Action Network
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
CA-19-9 - Diagnostic Kit
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma | BMC Cancer | Full Text